Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Race Oncology Ltd (RAC)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.315 +0.055    +4.37%
07:04:59 - Closed. Currency in AUD ( Disclaimer )
  • Volume: 115,266
  • Bid/Ask: 1.315 / 1.315
  • Day's Range: 1.255 - 1.325
Type:  Equity
Market:  Australia
ISIN:  AU000000RAC3 
Race Oncology 1.315 +0.055 +4.37%

Race Oncology Company Profile

 
Read the Race Oncology Ltd company profile to learn more about the business and the management team. View Race Oncology Ltd facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

-

Equity Type

ORD

Race Oncology Limited, a clinical stage global biotechnology company, focuses on cancer care. Its lead product, bisantrene, is a small molecule anthracene chemotherapeutic. The company is developing bisantrene to address the unmet need of patients across multiple oncology indications, exploring anti-cancer plus cardio-protection. It is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the potent inhibitor of FTO (Fat mass and obesity-associated protein). The company is in collaboration with City of Hope, MD Anderson, Sheba City of Health, and UNC School of Medicine. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.

Contact Information

Address Gateway, 1 Macquarie Place Level 36
Sydney, 2000
Australia
Phone 61 2 8051 3043
Fax 61 2 8051 3043

Top Executives

Name Age Since Title
Nicholas George Kirk 60 2004 Chief Executive Officer, Managing Director and Executive Director
Jack Theseus Lowenstein 66 2000 Non-Executive Director
Anthony Vincent Connon 71 2007 Non-Executive Director
D. Williams - 2014 Non-Executive Director
Stephen B. Humphrys - 2014 Non-Executive Director
R. B. Kelly - 2014 Chairman
Martin S. Tallman - 2016 Member of Scientific Advisory Board
Roland Walter - - Member of Scientific Advisory Board
Borje S. Andersson - 2019 Chairman of Clinical Advisory Board
Douglas Smith - - Member of Scientific Advisory Board
Jaap-Jan Boelens - 2020 Member of Clinical Advisory Board
James Breitenbucher - 2022 Member of Scientific Advisory Board
Phillip R. Lynch - 2020 Non-Executive Director
Jianjun Chen - 2021 Member of Scientific Advisory Board
Mary Harney - 2021 Independent Non-Executive Chair
Peter M. Smith 60 2023 Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RAC Price Commentary

Write your thoughts about Race Oncology Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Raghav Aggarwal
Raghav Aggarwal Jul 18, 2018 5:28
Saved. See Saved Items.
This comment has already been saved in your Saved Items
If we are looking for boom investors will get real in 5yr.?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email